ViraTherapeutics

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Endpoints
Thu, 09/13/18 - 11:30 am
Boehringer Ingelheim
ViraTherapeutics
M&A
Boehringer Beats A Brave Route With Oncolytic Virus Deal
Seeking Alpha
Fri, 10/7/16 - 09:03 am
Boehringer Ingelheim
VSV-GP
ViraTherapeutics